FDA Greenlights Roche's Tecentriq Combined with Lurbinectedin as Initial Maintenance Treatment for Advanced Small Cell Lung Cancer

FDA Approval: The FDA has approved the combination of Tecentriq® (atezolizumab) and lurbinectedin (Zepzelca®) for the first-line maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC), marking it as the first and only therapy of its kind for this aggressive disease.

Clinical Efficacy: The combination therapy demonstrated a 46% reduction in the risk of disease progression or death and a 27% reduction in the risk of death compared to Tecentriq alone, with median overall survival increasing from 10.6 months to 13.2 months.